US › Healthcare

Immuneering Corp (IMRX)

US · Healthcare · Biotechnology

$4.46+0.22%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$360,958

Net profit

$-17.3M

EPS

$-0.27

EPS estimate

$-0.26

Net margin

-4,784.6%

EPS came in at -0.27 against a street estimate of -0.26 — a miss of 3.8%.

Key statistics

Market cap

$276.3M

Forward P/E

0.0

P/B

1.44

Book value

$2.95

EPS (TTM)

$-0.93

52-week high

$10.08

52-week low

$3.86

50-day MA

$4.82

200-day MA

$5.21

Beta

0.39

Analyst view

Analysts rate Immuneering Corp a buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $17.17.

Shareholding

Insiders

13.82%

Institutions

55.59%

Largest institutional holders

Fund	Stake
FMR Inc	14.99%
Sanofi	4.19%
Vanguard Capital Management, LLC	3.54%
Marshall Wace Asset Management Ltd	3.09%
T. Rowe Price Associates, Inc.	2.83%
BlackRock Inc	2.33%
DCF Advisers, LLC	1.22%
Geode Capital Management, LLC	0.99%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Immuneering Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.